 therapy recombinant granulocyte colony-stimulating factor erythropoietin decreases toxicity zidovudine Twenty-two patients acquired immunodeficiency syndrome AIDS severe AIDS-related complex multilineage hematopoietic defects recombinant granulocyte colony-stimulating factor G-CSF erythropoietin EPO phase I/II trial patients neutropenic anemic withdrawal bone marrow-suppressive drugs Daily G-CSF self-administered absolute neutrophil count ANC weeks Subcutaneous EPO regimen dose increase g/L hemoglobin Groups patients doses zidovudine tolerance G-CSF EPO therapy dose modification ANC g/L dose zidovudine patients G-CSF mean increase neutrophils weeks Significant increases cell number lymphocyte proliferative response bone marrow cellularity EPO therapy hemoglobin evaluable patients weeks Sixteen patients mg patients mg zidovudine day reinstitution zidovudine decline reticulocytes hemoglobin reappearance transfusion requirements patients study medications No patient study medications neutropenia thrombocytopenia Toxicities mild dose modifications dilution plasma lymphocyte co-cultures HIV serum antigen levels G-CSF G-CSF EPO therapy HIV antigen zidovudine therapy Opportunistic infections patients myelosuppressive antimicrobial agents ganciclovir development neutropenia results combined therapy G-CSF EPO neutropenia anemia AIDS therapy resumption full-dose zidovudine patients intolerant hematologic effects zidovudine apparent alteration HIV expression efficacy zidovudine